Author

K. Savvatakis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

J. T. Siveke· 2 shared P. F. Cheung· 2 shared A. Bazarna· 1 shared A. M. Winkelkotte· 1 shared A. Paschen· 1 shared A. Tannapfel· 1 shared A. W. Chan· 1 shared A. Walch· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. T. Siveke

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma

I. Heid, S. Karakaya, C. Muench, S. S. Lueong, A. M. Winkelkotte, S. T. Liffers, L. Godfrey, P. F. Cheung, K. Savvatakis, G. J. Topping, F. Englert, L. Kritzner, M. Grashei, T. Kunzke, N. Sun, , J. T. Siveke

This study identifies functional metabolic differences between PDAC subtypes and shows that non-invasive HP-MRS can detect glycolytic tumor metabolism.

bioRxiv · Jul 23, 2021 · PreprintCancer Biology

Progranulin promotes immune evasion of pancreatic adenocarcinoma through regulation of MHCI expression

P. F. Cheung, J. Yang, K. Krengel, K. Althoff, C. Yip, E. H. Siu, L. W. Ng, K. S. Lang, L. Cham, D. R. Engel, C. Soun, I. Cima, B. Scheffler, J. K. Striefler, M. Sinn, , J. T. Siveke

This study shows that tumor-derived progranulin (PGRN) promotes immune evasion in pancreatic ductal adenocarcinoma by reducing MHC class I expression, and blocking PGRN enhances immune response and slows tumor progression.

bioRxiv · Feb 24, 2021 · PreprintCancer Biology